Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2019, Vol. 46 Issue (5): 833-835    DOI: 10.12891/ceog4876.2019
Case Report Previous articles | Next articles
Effects of tadalafil on the uterine artery of fetal growth restriction
S. Magawa1, *(), H. Tanaka1, S. Maki1, M. Nii1, T. Umekawa1, T. Ikeda1
1Department of Obstetrics and Gynecology, Mie University Faculty Medicine, Mie, Japan
Download:  PDF(288KB)  ( 155 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Fetal growth restriction (FGR) is the most important cause of perinatal morbidity and mortality during the perinatal period. However, there is no established standard regarding the appropriate delivery time or treatment methods for fetuses with FGR. Reduced uterine arterial blood flow has been reported with FGR; however, if this is improved, then FGR may also be improved. Phosphodiesterase 5 inhibitors have vasodilating actions. When administered to the mother, they may improve FGR by improving fetal placental blood flow through improvements in uterine arterial blood flow.

Key words:  Uterine artery bold flow      Fetal growth restriction      PDE5 inhibitor      Tadalafil      Fetus     
Published:  10 October 2019     
*Corresponding Author(s):  S. MAGAWA     E-mail:  shoichimagawa@yahoo.co.jp

Cite this article: 

S. Magawa, H. Tanaka, S. Maki, M. Nii, T. Umekawa, T. Ikeda. Effects of tadalafil on the uterine artery of fetal growth restriction. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 833-835.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog4876.2019     OR     https://ceog.imrpress.com/EN/Y2019/V46/I5/833

[1] K. Nakanishi, Y. Oishi, T. Miyamoto, E. Nakamura, K. Murakami, M. Ono, A. Nozawa, S. Kitamura, K. Sengoku. Anti-E alloimmunization in a pregnancy with a low antibody titer[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 614-616.
[2] N. Wibowo, R. Irwinda, A.T. Rivai. Serum zinc, selenium, iron, and copper levels in pregnant women with fetal growth restriction[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 892-896.
[3] Yajing Zhu, Hongmei Ma, Wei Ma. Transthyretin and retinol-binding protein 4 in patients with fetal growth restriction[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 270-273.
[4] M. Hosokawa, M. Waratani, T. Yasuo, K. Iwasa, J. Kitawaki. Intestinal volvulus without malrotation in a dichorionic diamniotic twin: case report and review of literature[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(1): 154-156.
[5] Shigeo Iijima. A case of body stalk anomaly: the value of adding fetal magnetic resonance imaging to ultrasonography for perinatal management[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 930-932.
[6] H. Tanaka, S. Maki, M. Kubo, H. Yuasa, T. Umekawa, T. Ikeda. Treatment using tadalafil for dichorionic diamniotic twin pregnancy with fetal growth restriction[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(4): 591-593.
[7] Ze Chen, Xiaoping Lei, Yongjun Zhang. The effects of fetal gender on pregnancy induced hypertension in twin pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(3): 353-356.
[8] H.X. Zhang, X.F. You, X. Wei, M.H. Sun. Fetal magnetic resonance imaging (MRI) analysis of seven cases of obstetric mirror syndrome (OMS)[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(6): 892-898.
[9] J.C. Han, M. Hornick, H.S. Ko, X. Yang, Y.H. He. Severe tortuous intra-abdominal segment of isolated single umbilical artery by three-dimensional high-definition flow imaging[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(6): 956-957.
[10] T. Çift, E. Ertan Palabiyik, E. Korkmazer, T. Güçlü, E. Arslan Yildirim. Complete hydatidiform mole and a coexistent viable fetus: a case report and review of the literature[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(4): 642-644.
[11] H.L. Liu, F. Yan, H.P. Sun, G.Q. Li, F. Ai, X.D. Dong. Ultrasonography of fetal cleft lip and palate in first-trimester[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(3): 408-412.
[12] W. Gong, L. Liang, D.G. Zheng, R.S. Zhong, Y.X. Zhu, Y.J. Wen. A case report of fetal malignant immature mediastinal teratoma[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(3): 496-498.
[13] M. Al-Azemi, R. Raghupathy, F. Azizieh. Pro-inflammatory and anti-inflammatory cytokine profiles in fetal growth restriction[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(1): 98-103.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] Sandeep K. Krishnan, Norman E. Lepor. Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management[J]. Reviews in Cardiovascular Medicine, 2016, 17(S1): 9 -21 .
[3] Ibrahim Sidiqi, Patrick Alexander. Current Advances in Endovascular Therapy for Infrapopliteal Artery Disease[J]. Reviews in Cardiovascular Medicine, 2015, 16(1): 36 -50 .
[4] Peter Shalit. Management of Dyslipidemia in Patients With Human Immunodeficiency Virus[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 38 -46 .
[5] Sophie Mavrogeni, Fabrizio Cantini, Gerald M. Pohost. Systemic Vasculitis: An Underestimated Cause of Heart Failure—Assessment by Cardiovascular Magnetic Resonance[J]. Reviews in Cardiovascular Medicine, 2013, 14(1): 49 -55 .
[6] George L. Smith. Appropriate Use Criteria: The Gold Standard, or a Mechanism for the Derogation of Clinical Judgment?[J]. Reviews in Cardiovascular Medicine, 2011, 12(2): 105 .
[7] Prabhjot Singh Nijjar, Anoop Parameswaran, Aman M. Amanullah. Evaluation of Anomalous Aortic Origins of the Coronaries by 64-Slice Cardiac Computed Tomography[J]. Reviews in Cardiovascular Medicine, 2007, 8(3): 175 -181 .
[8] . SELF-ASSESSMENT POST-TEST[J]. Reviews in Cardiovascular Medicine, 2006, 7(S2): 51 -52 .
[9] Alice K. Jacobs. Gender Differences in Coronary Revascularization: Does Age Make a Difference?[J]. Reviews in Cardiovascular Medicine, 2004, 5(1): 68 -70 .
[10] Jeffrey W. Moses, Stephane Carlier, Issam Moussa. Lesion Preparation Prior to Stenting[J]. Reviews in Cardiovascular Medicine, 2004, 5(S2): 16 -21 .